MiR-337 Suppresses Cutaneous T-cell Lymphoma Via the STAT3 Pathway

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2019 Jun 20

PMID 31213131

Citations 4

Authors

Liang Xia

Linlin Wu

Hailong Xia

Jing Bao

Qingsheng Li

Xiaowen Chen

Ruixiang Xia

Affiliations

Soon will be listed here.

Abstract

Cutaneous T-cell lymphoma (CTCL) is associated with the downregulation of miR-337 expression, although the exact underlying mechanism is unknown. In the present work, we investigated the molecular mechanism and function of miR-337 in regulating CTCL cell viability and invasion. We observed that miR-337 expression was downregulated in both CTCL tumors and cell lines. Furthermore, CCK assay, BrdU incorporation assay, and flow cytometry revealed that transfection with the miR-337 mimic resulted in decreased proliferation and increased apoptotic levels in CTCL cells. Results of the Transwell migration assay indicated that the miR-337 mimic decreased CTCL cell invasion . Both bioinformatics prediction and the dual-luciferase reporter assay revealed that miR-337 targets the 3'-UTR of STAT3 for silencing. Overexpression of STAT3 counteracted the pro-apoptotic influence of miR-337 in CTCL cell lines and restored their invasion properties. The results thus indicate that the miR-337-STAT3 axis inhibits the proliferation of malignant T cells and that miR-337 may serve as a promising therapeutic target for CTCL.

Citing Articles

Epigenetic alterations and advancement of lymphoma treatment.

Zhuang S, Yang Z, Cui Z, Zhang Y, Che F Ann Hematol. 2023; 103(5):1435-1454.

PMID: 37581713 DOI: 10.1007/s00277-023-05395-z.

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.

Zhang P, Zhang M Front Oncol. 2021; 11:663961.

PMID: 34249700 PMC: 8263908. DOI: 10.3389/fonc.2021.663961.

Estradiol deficiency and skeletal muscle apoptosis: Possible contribution of microRNAs.

Karvinen S, Juppi H, Le G, Cabelka C, Mader T, Lowe D Exp Gerontol. 2021; 147:111267.

PMID: 33548486 PMC: 9897888. DOI: 10.1016/j.exger.2021.111267.

MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Gluud M, Willerslev-Olsen A, Gjerdrum L, Lindahl L, Buus T, Andersen M Cancers (Basel). 2020; 12(5).

PMID: 32414221 PMC: 7281391. DOI: 10.3390/cancers12051229.

References

Nielsen M, Kaestel C, Eriksen K, Woetmann A, Stokkedal T, Kaltoft K . Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999; 13(5):735-8. DOI: 10.1038/sj.leu.2401415. View

Eriksen K, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C . Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001; 15(5):787-93. DOI: 10.1038/sj.leu.2402093. View

Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K . Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002; 62(12):3351-5. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Yu H, Jove R . The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105. DOI: 10.1038/nrc1275. View

Willemze R, Jaffe E, Burg G, Cerroni L, Berti E, Swerdlow S . WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10):3768-85. DOI: 10.1182/blood-2004-09-3502. View

Krejsgaard T, Vetter-Kauczok C, Woetmann A, Lovato P, Labuda T, Eriksen K . Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 2006; 20(10):1759-66. DOI: 10.1038/sj.leu.2404350. View

Dobbeling U . Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas. Curr Drug Discov Technol. 2007; 4(1):24-30. DOI: 10.2174/157016307781115467. View

van Kester M, Out-Luiting J, von dem Borne P, Willemze R, Tensen C, Vermeer M . Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells. J Invest Dermatol. 2008; 128(7):1691-5. DOI: 10.1038/sj.jid.5701246. View

10.

Xiao C, Rajewsky K . MicroRNA control in the immune system: basic principles. Cell. 2009; 136(1):26-36. DOI: 10.1016/j.cell.2008.12.027. View

11.

Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

12.

Kopp K, Kauczok C, Lauenborg B, Krejsgaard T, Eriksen K, Zhang Q . COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia. 2010; 24(6):1179-85. DOI: 10.1038/leu.2010.66. View

13.

Ballabio E, Mitchell T, van Kester M, Taylor S, Dunlop H, Chi J . MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010; 116(7):1105-13. PMC: 2938132. DOI: 10.1182/blood-2009-12-256719. View

14.

Kamstrup M, Gjerdrum L, Biskup E, Lauenborg B, Ralfkiaer E, Woetmann A . Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2010; 116(14):2504-12. DOI: 10.1182/blood-2009-12-260216. View

15.

Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen K, Kopp K, Bonefeld C . Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol. 2011; 131(6):1331-8. DOI: 10.1038/jid.2011.27. View

16.

Ralfkiaer U, Hagedorn P, Bangsgaard N, Lovendorf M, Ahler C, Svensson L . Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011; 118(22):5891-900. PMC: 3342856. DOI: 10.1182/blood-2011-06-358382. View

17.

van der Fits L, Out-Luiting J, van Leeuwen M, Samsom J, Willemze R, Tensen C . Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome. J Invest Dermatol. 2011; 132(2):440-7. DOI: 10.1038/jid.2011.293. View

18.

Baigude H, Ahsanullah , Li Z, Zhou Y, Rana T . miR-TRAP: a benchtop chemical biology strategy to identify microRNA targets. Angew Chem Int Ed Engl. 2012; 51(24):5880-3. PMC: 3501383. DOI: 10.1002/anie.201201512. View

19.

Du L, Subauste M, DeSevo C, Zhao Z, Baker M, Borkowski R . miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012; 7(6):e39167. PMC: 3377607. DOI: 10.1371/journal.pone.0039167. View

20.

Kim S, Lee Y, Bae Y . MiR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting α subunit of protein kinase CKII in human colorectal cancer cells. Biochem Biophys Res Commun. 2012; 429(3-4):173-9. DOI: 10.1016/j.bbrc.2012.10.117. View